These events caused Amgen's stock price to drop. Plaintiff seeks to recover damages on behalf of the Class and is …
05/22/2013 2,150 Derivative/Non-derivative trans. at $58.43 per share. 125,624 05/22/2013 2,000 Derivative/Non-derivative trans. at $50.44 per share. 100,880 04/28/2013 91 Derivative/Non-derivative trans. at $108.38 per share. 9,863
On Sunday, the world's largest independent biotechnology company, Amgen Inc. (Nasdaq: AMGN), bought Onyx Pharmaceuticals Inc. (Nasdaq: ONXX) in a $10.4 billion dollar deal – making it the fifth-largest biotech deal in history …
Amgen Inc has reached a settlement with AbbVie Inc that will delay the U.S. launch of Amgen's cheaper biosimilar version of AbbVie's cash cow, the blockbuster rheumatoid arthritis drug Humira, until Jan. 31, 2023, the companies said on …
"But giving the way the stock is reacting, maybe we're coming close to finding a bottom here." In the technology sector, Brady said Nokia has good fundamentals, so he's inclined to hold onto Nokia. He also said Amgen is a terrific company …
A federal judge rejected Amgen Inc.'s effort to temporarily block a competitor from releasing a copycat version of one of its top-selling biologic drugs. The Thousand Oaks biotech company had accused Novartis subsidiary Sandoz of violating …